Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

44.35
-0.2406-0.54%
Post-market: 44.450.0967+0.22%19:30 EDT
Volume:16.59K
Turnover:734.60K
Market Cap:214.67M
PE:- -
High:44.71
Open:44.71
Low:43.60
Close:44.59
52wk High:47.00
52wk Low:26.29
Shares:4.84M
Float Shares:4.84M
Volume Ratio:0.60
T/O Rate:0.34%
Dividend:0.02
Dividend Rate:0.04%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 06

Amazon Pharmacy to Offer GLP-1 Weight-Loss Medications to Medicare Part D Patients

Dow Jones
·
Aug 06

Eli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley

TIPRANKS
·
Aug 06

Wells Fargo Adjusts PT on Eli Lilly and Co. to $1,330 From $1,280, Maintains Overweight Rating

MT Newswires Live
·
Aug 06

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS
·
Aug 06

Eli Lilly Buy Rating Reaffirmed as Obesity Leadership Drives Outlook; Price Target Raised to $1,344 from $1,334

TIPRANKS
·
Aug 06

Street View: Lilly Remains the Front-Runner as GLP-1 Demand Climbs

Reuters
·
Aug 06

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

Benzinga Earnings
·
Aug 06

Eli Lilly (LLY) Stock Climbs On GLP 1 Strength And 86% Margin

Simply Wall St.
·
Aug 06

Eli Lilly : Leerink Partners Raises Target Price to $1,309.00 from $1,232.00

THOMSON REUTERS
·
Aug 06

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy

Dow Jones
·
Aug 06

Eli Lilly Earnings Call Highlights Powerful Growth Momentum

TIPRANKS
·
Aug 06

Global Equities Roundup: Market Talk

Dow Jones
·
Aug 06

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Reuters
·
Aug 06

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Eli Lilly & Co. Stock Advances 4.9%, Outperforms Peers

Dow Jones
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS
·
Aug 06

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.

Dow Jones
·
Aug 06